However, despite the lack of toxicity of the CD3ζ-based FAP-specific CAR-T cells, FAP-KIRS2/DAP12 CAR-T cells showed similar toxicity to the one reported by Roberts et al. in the aforementioned study, suggesting that higher efficacy of FAP targeting is also associated with higher risk of on-target/off-tumor toxicity (173). The gene discussed is TYROBP; the disease is neoplasm.